Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Bahrain grants emergency use for Pfizer, BioNTech vaccine

12/04/2020 | 11:55am EST

DUBAI, United Arab Emirates — The island kingdom of Bahrain said Friday it has become the second nation in the world to grant an emergency-use authorization for the coronavirus vaccine made by Pfizer and its German partner BioNTech.

The state-run Bahrain News Agency made the announcement on Friday night, following an earlier announcement by the United Kingdom on Wednesday, making Britain the first in the world.

“The confirmation of approval by the National Health Regulatory Authority of the kingdom of Bahrain followed thorough analysis and review undertaken by the authority of all available data,” the kingdom said on its state-run Bahrain News Agency.

Bahrain did not say how may vaccines it has purchased. It did not immediately respond to questions from The Associated Press.

Bahrain had already granted emergency-use authorization for a Chinese vaccine made by Sinopharm.

Bahrain, home to the U.S. Navy’s 5th Fleet, is a small island off the coast of Saudi Arabia in the Persian Gulf.

With a population of 1.6 million, it has reported more than 87,000 cases and 341 deaths, according to the government. Over 85,000 people have recovered from the COVID-19 illness that is caused by the virus.

The country is also home to a large expatriate population, with many low-paid labourers from southeast Asia living in tight housing. In July, authorities told the AP they had moved 8,000 labourers to new accommodations, disinfected housing and implemented a rule requiring no more than five labourers per room, with about 3 metres (10 feet) of space for each one.

The Bahraini government says it has conducted over 2 million coronavirus tests across the island. It initially blamed its higher per-capita infection rate on that.

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.91% 106.29 Delayed Quote.30.39%
PFIZER INC. 0.08% 37.31 Delayed Quote.1.36%
All news about PFIZER INC.
05:42pCanada seeking reassurance as Europe mulls export controls on COVID-19 vaccin..
AQ
05:14pPFIZER : Nova Scotia premier defends conservative vaccine rollout, voices supply..
AQ
05:08pPFIZER : Biden administration to boost vaccine supply amid shortages
AQ
04:30pBiden administration to purchase 200 mln new doses total of pfizer, moderna v..
RE
04:07pMODERNA : Biden Administration Officials Told Governors They Will Increase Weekl..
DJ
02:54pPfizer working on booster shot to protect against COVID-19 variants
RE
01:46pJohnson & Johnson's Profit Is Boosted by Pharmaceuticals Business -- 2nd Upda..
DJ
01:22pBiden administration aims to have enough vaccine for most Americans by summer..
RE
01:18pASTRAZENECA : Italy asks EU to take action against Pfizer over COVID-19 vaccine ..
RE
01:09pSanofi to help produce 100 million Pfizer/BioNTech vaccine doses
RE
More news
Financials (USD)
Sales 2020 47 233 M - -
Net income 2020 19 801 M - -
Net Debt 2020 43 412 M - -
P/E ratio 2020 12,0x
Yield 2020 3,90%
Capitalization 207 B 207 B -
EV / Sales 2020 5,31x
EV / Sales 2021 4,34x
Nbr of Employees 88 300
Free-Float 59,1%
Chart PFIZER INC.
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 41,71 $
Last Close Price 37,31 $
Spread / Highest target 42,1%
Spread / Average Target 11,8%
Spread / Lowest Target -3,51%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.1.36%207 217
JOHNSON & JOHNSON5.46%436 949
ROCHE HOLDING AG3.82%309 894
NOVARTIS AG2.96%220 401
MERCK & CO., INC.-0.79%205 312
ABBVIE INC.3.13%195 085